TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04511000

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lipilou®(generic atorvastatin drug) 20 mg
Description: Patients assigned to experimental group are treated with Lipilou® 20 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lipilou®(generic atorvastatin drug) 10 mg
Description: Patients assigned to comparator group are treated with Lipilou® 10 mg
Study: NCT00636480

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ChloraPrep One Step
Description: Administer topically

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sterile saline
Description: 0.9% NaCl solution
Study: NCT01488955

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: 400 mg oral once a day from day 0 for 3 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosfomycin-Trometamol
Description: 8 g granulate with 3 g Fosfomycin-Trometamol oral once at day 0, placebo to Ibuprofen once a day oral from day 0 for 3 days
Study: NCT04553445

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Chronotype
Description: Participants screened using the Morningness/Eveningness Questionnaire. Chronotype categorized as either Definite Morning/Morning, or Evening/Definite Evening. Participant will exercise (60-70% estimated heart rate max, 2 x per week, 30-min/session) either in sync or not in sync with chronotype for one month in a randomized cross-over design. There will be a one-month wash out period, and then participant will complete training in the alternate chronotype for one month.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Green exercise
Description: Participants will be randomly assigned to four weeks of moderate intensity aerobic exercise (60-70% estimated heart rate max, 2 x per week, 30-min/session) in either natural or indoor environments in a randomized cross-over design. There will be a one-month wash out period, and then participant will complete training in alternate environment for one month.
Study: NCT01906983

Intervention type: OTHER
Intervention: Doppler Ultrasound
Description: Doppler ultrasound will be performed to patients with blunt splenic trauma, prior to discharge and again, at 3-6 months in patients with thrombosis indication.
Study: NCT01389414

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab plus GEMOX chemotherapy
Description: panitumumab 6 mg/kg will be administered over 60 minute +/- 15 minutes on day 1 followed by Gemcitabine 1000mg/sqm administered by intravenous infusion as 1-hour infusion on day 1 of each cycle. Oxaliplatin 100mg/sqm will be administered by intravenous infusion as 2-hour infusion on day 2 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GEMOX chemotherapy
Description: Gemcitabine 1000mg/sqm will be administered by intravenous infusion as 1-hour infusion on day 1 of each cycle. Oxaliplatin 100mg/sqm will be administered by intravenous infusion as 2-hour infusion on day 2 of each cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GEMOX chemotherapy
Description: Gemcitabine 1000mg/sqm will be administered by intravenous infusion as 1-hour infusion on day 1 of each cycle. Oxaliplatin 100mg/sqm will be administered by intravenous infusion as 2-hour infusion on day 2 of each cycle.
Study: NCT03163043

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Amino Acid Intake
Description: Amino acid intakes will be varied at 0.2-2.67 g/kg/d
Study: NCT02731911

Intervention type: DRUG
Intervention: dexamethasone intravitreal implant
Description: Ozurdex® treatment for diabetic macular oedema as per standard of care in clinical practice.
Study: NCT03669198

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: NT-Pro BNP
Description: . AHF patients who met inclusion and exclusion criteria were randomly assigned to 2 groups, NT-pro BNP group and control group. In the NT-pro BNP group, serial NT-pro BNP levels at admission and pre-discharge was measured, the latter with the target of decrease ≥ 30% NT-pro BNP level. Randomised patients were followed during treatment up to 90 days post-discharge to assess short-term outcomes and costs.
Study: NCT01278706

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endometrial biopsy/ies
Description: performing office endometrial biopsy with a disposable sterile catheter

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endometrial biopsy/ies
Description: performing office endometrial biopsy with a disposable sterile catheter

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endometrial biopsy/ies
Description: performing office endometrial biopsy with a disposable sterile catheter
Study: NCT02994784

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propylene Glycol-Free Melphalan Hydrochloride
Description: Intravenous Propylene Glycol-Free Melphalan Hydrochloride
Study: NCT02383992

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 3% H2O2 solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.9% normal saline
Study: NCT02484378

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CER-001
Description: Engineered pre-beta HDL particle

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline
Study: NCT04120376

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contraception Counseling
Description: Each participant will receive a 10 minute confidential contraception counseling session with an APP in the Emergency Department
Study: NCT04950036

Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnostic Test
Description: The results of hip arthroscopy were taken as the gold standard and MRI examination was taken as the research object.

Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnostic Test
Description: The results of hip arthroscopy were taken as the gold standard and MRI examination was taken as the research object.

Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnostic Test
Description: The results of hip arthroscopy were taken as the gold standard and MRI examination was taken as the research object.
Study: NCT00151398

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lecozotan SR
Description: evaluation of long term therapy with 3 doses of lecozotan sr ( 2, 5, and 10 mg)administered to patients with AD who have completed week 12 evaluations in the short-term study. Patient duration is 42 weeks.~Arms include lecozotan sr 2 mg, 5mg, and 10 mg as well as donepezil.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lecozotan SR
Description: evaluation of long term therapy with 3 doses of lecozotan sr ( 2, 5, and 10 mg)administered to patients with AD who have completed week 12 evaluations in the short-term study. Patient duration is 42 weeks.~Arms include lecozotan sr 2 mg, 5mg, and 10 mg as well as donepezil.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lecozotan SR
Description: evaluation of long term therapy with 3 doses of lecozotan sr ( 2, 5, and 10 mg)administered to patients with AD who have completed week 12 evaluations in the short-term study. Patient duration is 42 weeks.~Arms include lecozotan sr 2 mg, 5mg, and 10 mg as well as donepezil.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Donepezil
Description: 10 mg donepezil QD dosed up to 40 weeks
Study: NCT00518856

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neonatal resuscitation protocol
Description: training in neonatal resuscitation and sepsis identification early treatment

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: continued with current standard of care for birth attendants
Study: NCT01973140

Intervention type: DRUG
Group type: OTHER
Intervention: Tolvaptan
Description: Adult male volunteers will be given a given a 60mg or a 30 mg dose of tolvaptan. Blood and urine samples will be collected at specified time points for the next 24 hours.

Intervention type: DRUG
Group type: OTHER
Intervention: Hypertonic saline infusion
Description: A week after the first intervention(tolvaptan), the subjects will undergo a hypertonic saline infusion for 6 hours. Blood and urine samples will be collected at specified time points until 4hour hours after the infusion.
Study: NCT01598103

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAF312
Description: One week of treatment in a BID (two times a day) regimen (hard gelatin capsules for oral use)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to SAF312
Description: One week of treatment in a BID (two times a day) regimen (hard gelatin capsules for oral use)
Study: NCT00629005

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Constraint-Induced Movement Therapy + strength training
Description: Participants wears a mitt on non-paretic hand for 90% of waking hours and completes 3 hours of functional task practice (e.g., flipping cards, putting coins in coin slot, putting cans on a shelf) plus 1 hour of resistance elastic band exercises

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Constraint-Induced Movement Therapy + range of motion
Description: Participants wears a mitt on non-paretic hand for 90% of waking hours and completes 3 hours of functional task practice (e.g., flipping cards, putting coins in coin slot, putting cans on a shelf) plus 1 hour of unresisted arm movements for
Study: NCT02617979

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SAFECARE at Home customized lessons
Study: NCT01063894

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: breakfast cereal
Description: breakfast cereal and milk

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: water
Description: water
Study: NCT01836185

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evacetrapib
Study: NCT03703726

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Reference meal
Description: 50 g of Commercial Rice (Jasmin Rice) (dry weight) was cooked and 4 mg iron from Ferrous sulphate was added Prior to give to participants. Rice meal consumed with mixed vegetable Sauce.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Test meal A
Description: Commercial Rice (Jasmin Rice) was mixed with iron fortified extruded rice co-fortified with zinc sulfate, Rice meal consumed with mixed vegetable Sauce.~Cold temperature extruding process (30-40 C°) was used to produce the extruded rice.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Test meal B
Description: Commercial Rice (Jasmin Rice) was mixed with iron fortified extruded rice co-fortified with zinc sulfate, Rice meal consumed with mixed vegetable Sauce.~Warm temperature extruding process (60-70 C°) was used to produce the extruded rice

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Test meal C
Description: Commercial Rice (Jasmin Rice) was mixed with iron fortified extruded rice co-fortified with zinc sulfate, Rice meal consumed with mixed vegetable Sauce.~Hot temperature extruding process (80-100 °C) was used to produce the extruded rice.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Test meal D
Description: Commercial Rice (Jasmin Rice) was mixed with iron fortified extruded rice co-fortified with zinc sulfate,citric acid and trisodium Citrate. Rice meal consumed with mixed vegetable Sauce.~Cold temperature extruding process (30-40 C°) was used to produce the extruded rice.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Test meal E
Description: Commercial Rice (Jasmin Rice) was mixed with iron fortified extruded rice co-fortified with zinc sulfate,citric acid and trisodium Citrate. Rice meal consumed with mixed vegetable Sauce.~warm temperature extruding process (60-70 C°) was used to produce the extruded rice.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Test meal F
Description: Commercial Rice (Jasmin Rice) was mixed with iron fortified extruded rice co-fortified with zinc sulfate,citric acid and trisodium Citrate. Rice meal consumed with mixed vegetable Sauce.~Hot temperature extruding process (80-100 C°) was used to produce the extruded rice.
Study: NCT04654962

Intervention type: PROCEDURE
Intervention: Anesthetic nerve block
Description: iliac fascia block is an analgesic technique that uses local anesthesia, is effective and relatively safe in preoperative management. The target of this block is the femoral and lateral femoral cutaneous nerves; which innervate the anterior aspect of the thigh, as well as the muscle and periosteum that covers the femoral head, neck and proximal femur.
Study: NCT03085199

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Laparoscopic reinforcement suture
Description: After cutting of duodenal stump of about 2 cm length using linear stapler, LARS commenced from upper to lower part on staple-line of duodenal stump. Continuous suture with invagination was performed using a barbed suture. In case of patient with short duodenal stump because of chronic ulcer or ectopic pancreas at duodenal bulb, 2 or 3 interrupted sutures without invagination of duodenal stump was conducted using barbed sutures.
Study: NCT03069144

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HAT1 topical solution
Description: HAT1 topical solution will be applied twice daily. The research team will provide instructions for the correct application of the treatment. If a lesion disappears, patients will continue applying the cream twice daily to the area. No additional creams, lotions or soaps other than provided test products will be allowed throughout the duration of the study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcipotriol
Description: Calcipotriol ointment (0.005%) will be applied twice daily. The research team will provide instructions for the correct application of the treatment. If a lesion disappears, patients will continue applying the cream twice daily to the area. No additional creams, lotions or soaps other than provided test products will be allowed throughout the duration of the study.
Study: NCT01134471

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ostene
Description: applied to sternal surface

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bonewax
Description: applied to sternal surface
Study: NCT01836185

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evacetrapib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evacetrapib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evacetrapib
Study: NCT02907619

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-06252616
Description: Either 5mg/kg, 20mg/kg or 40mg/kg will be assigned to a subject based on their maximum tolerated dose from B5161002
Study: NCT04012346

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial magnetic stimulation
Description: Transcranial magnetic stimulation device will be used. Short protocol iTBS will be applied.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial magnetic stimulation
Description: Transcranial magnetic stimulation device will be used. Short protocol iTBS will be applied.
Study: NCT04043208

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Biofeedback
Description: Three sessions of biofeedback will be performed during the first 3 weeks of the intervention period. Biofeedback sessions will be performed 30 min after ingestion of the offending meal: patients will be taught to control abdominal and thoracic muscular activity by providing a visual display of the abdominal and thoracic perimeter; specifically, they will be instructed to reduce the abdominal perimeter (girth). Patients will be instructed to perform the same exercises before and after breakfast, lunch and dinner during the 4-week intervention period.
Study: NCT01124071

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Provision of 2 Korean meals per day 6 days per week
Description: At each participant's baseline visit, participant's will have an individualised lifestyle session addressing dietary and exercise goals and techniques to achieve weight loss. Participants in the Korean diet group will pick up lunch and evening meals Monday-Friday. Raw ingredients and cooking instructions will also be provided on friday for saturday meal preparation. Ongoing lifestyle sessions will be performed weekly for participants.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Western Diet
Description: At each participant's baseline visit, participant's will have an individualised lifestyle session addressing dietary and exercise goals and techniques to achieve weight loss. Participants in the Western diet group will be provided with a Western recipe cookbook and food vouchers (weekly) to purchase the necessary ingredients for the Western meal preparation. Ongoing lifestyle sessions will be performed weekly for participants.
Study: NCT00907192

Intervention type: BEHAVIORAL
Intervention: Personal Interview
Description: Interview questions about use of pain drugs and other knowledge and/or attitudes about them. Take about 5-10 minutes to complete.

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: 5 short questionnaires about use of pain drugs, attitudes about the pain drugs and their use, and concerns about use of these pain drugs. Take about 10-15 minutes to complete.
Study: NCT01240889

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone
Description: nasal spray

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticason
Description: 2 sprays per day in each nostril
Study: NCT04544865

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Staple Line Reinforcement
Description: ENDOPATH ECHELON Staple Line Reinforcement is used for reinforcement of staple lines during lung resection and bariatric surgical procedures, according to instructions for use.
Study: NCT04043208

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Three sessions will be performed during the first 3 weeks of the intervention period. Each session will be performed 30 min after ingestion of the offending meal: abdominal and thoracic perimeter will be recorded but not shown to the patient; patients will take a pill of placebo containing 0.5 g glucose and no specific instructions will be provided. Patients will be instructed to take a pill of placebo before breakfast, lunch and dinner during the 4-week intervention period.
Study: NCT00508157

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: Tablets, Oral, 5 to 30 mg, once daily, 16 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Continued Antipsychotic (Risperidone or Quetiapine or Olanzapine)
Description: Tablets, Oral, According to summary of product characteristics (SmPC)
Study: NCT04448639

Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardigraphy (ECHO)
Description: Standar 12 lead electrocardiogram

Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardigraphy (ECHO)
Description: Standar 12 lead electrocardiogram

Intervention type: DIAGNOSTIC_TEST
Intervention: Bloodtest
Description: cardiac biomarkers
Study: NCT03373851

Intervention type: DEVICE
Intervention: Zalviso Device
Description: The Zalviso device will be provided immediately before the Post anesthesia care unit (PACU) discharge. Patients will be queried every day during three postoperative days for the ability to use the device, their satisfaction, the level of pain, and the incidence of side effects. There will be no changes in usual care.~In the end of this study ward nurses carrying Zalviso patients will be asked to provide their usability and satisfaction evaluation for Zalviso device management. Physical therapist will be asked to provide their satisfaction regarding patients' ability to follow physical therapy program.
Study: NCT01704443

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Psychoeducational Treatment
Description: The Group Psychoeducational Treatment consists of treatment in small group format (8-9 women). Each session will be 2.25 hours in duration and there will be four, bi-weekly sessions over the course of 2 months. Session content includes education about chronic pain, PVD, stress and sexual response, mindfulness practices, and cognitive techniques to notice thought patterns that contribute to increased pain.~Participants in the Waitlist Control Condition will receive this treatment at the end of the waitlist period (approximately 8 weeks)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Waitlist control
Description: No treatment will be provided during the 8 week Waitlist control period
Study: NCT00979693

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: psilocybin
Description: 25 mg psilocybin administered orally once during each of the two day-long psychotherapy sessions.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: psilocybin
Description: 4 mg psilocybin orally administered once during each of two day-long psychotherapy session
Study: NCT01657799

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veliparib
Description: Veliparib capsules for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veliparib
Description: Veliparib capsules for oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to veliparib capsules for oral administration

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Whole brain radiation therapy
Description: 30.0 grays (Gy) of WBRT given in 10 daily fractions of 3.0 Gy each, excluding weekends and holidays

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Whole brain radiation therapy
Description: 30.0 grays (Gy) of WBRT given in 10 daily fractions of 3.0 Gy each, excluding weekends and holidays

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Whole brain radiation therapy
Description: 30.0 grays (Gy) of WBRT given in 10 daily fractions of 3.0 Gy each, excluding weekends and holidays
Study: NCT01803334

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Marking abdomen
Description: If the patient is randomized to the marking the abdomen group (study group) she will then have the anticipated incision needed to place the trocars during her surgery marked on her abdomen by the surgeon attending physician involved in the patient care during the preoperative counseling visit.